BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 19, 2010
View Archived Issues
Forest Gets Complete Response Letter for COPD Drug Daxas
As expected by most analysts, Forest Laboratories Inc. and Nycomed GmbH Monday night received a complete response letter for their chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast). (BioWorld Today)
Read More
ConjuChem Wants to Recapitalize with $35M from New Investors
Read More
Study Reports 'Smoke Sensor' Behind Emphysema's Ravages
Read More
PregLem's Esmya Positive in Phase III Uterine Fibroid Trial
Read More
Other News To Note
Read More
Stock Movers
Read More
Clinic Roundup
Read More
ATS Roundup
Read More